The cooperation between AMAG and Norgine is just one example of the license. Other recent examples of this strategy are Biogen (NASDAQ:BIIB) and Sangamo Therapeutics (NASDAQ:SGMO), which have entered into a global licensing agreement for the development of drugs for the treatment of neurological diseases, including Alzheimer`s and Parkinson`s. Dublin, April 08, 2020 (GLOBE NEWSWIRE) — The report ”Global Licensing Partnering Terms & Pharmaceutical Agreements, Biotech & Diagnostics 2014-2020” has been added to the ResearchAndMarkets.com. The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides unprecedented understanding and access to licensing agreements and agreements entered into by the world`s leading life science companies. The report provides details on the most recent licensing agreements announced in the pharmaceutical, biotechnology and diagnostic fields. The report is fully up-to-date and contains details on licensing agreements from 2014 to 2020. 8) How many different companies do you need to manage at the same time as a license manager looking for a live partner? THINK STRATEGICALLY ABOUT CHOICE OF LAW, FORUM SELECTION AND ARBITRATION CLAUSES A cooperation agreement can refer disputes to arbitration or remain silent about it and send default disputes to a court. As a first step, the parties should think strategically about the most appropriate option. In general, court proceedings offer greater possibilities for detection, the rights of jury proceedings and increased rights over appeal decisions. Differences in case law in contract law, and in particular the interpretation of what is meant by ”reasonable efforts” in the development of medicines, can have real consequences on the likelihood of success of a dispute. On the other hand, the arbitration procedure generally ensures faster resolution of disputes, confidentiality, the possibility of choosing the decision-makers in the settlement of the dispute and the finality of limited judicial review of the arbitration. Additional considerations arise when the parties do not have their headquarters in the United States. Arbitration can significantly limit the extent of discovery required in the event of a dispute.

This can be especially useful for companies that operate outside the U.S., as staff are less familiar or prepared for the requirements of U.S.-style Discovery procedures. 2) What is meant by ”field” in a license agreement? There is also the multinational pharmaceutical giant Merck (NYSE: MRK) and the Korean Hanmi Pharmaceutical (KRX: 008930). In mid-2020, they entered into an exclusive licensing agreement for efinopegdutide, Hanmis once a week in the review of the peptide 1/glucagon double agonist used to treat non-alcoholic steatohepatitis patients. MAKING A REASONABLE EFFORT CLAUSES OF THIS DEVELOPMENT PROJECT The question of whether a licensee has made the necessary efforts under the agreement to develop or commercialize a product is one of the most important (and frequently negotiated) issues under a licensing agreement. Depending on the jurisdiction, whether licensee accepts ”economically reasonable efforts”, ”reasonable efforts”, ”best efforts” or other standards in the development or marketing of a product may have a real impact on the likelihood of success of a dispute. It also affects the need to make expert statements, company-wide comparisons with other development projects, and/or industry-wide comparisons to determine whether a licensee`s actions comply with this standard in the event of a dispute. When elected, parties must be very conscious and work from the outset to clearly formulate guiding enemies in each agreement on the efforts needed to avoid future uncertainties. . . .